prothymosin alpha is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-07-19. Numbers and descriptions here follow the published literature rather than marketing material.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Merocrine glands – cells secrete their substances by exocytosis. (e.g. mucous and serous glands; also called "eccrine", e.g. major sweat glands of humans, goblet cells, salivary gland, tear gland and intestinal glands) Apocrine glands – a portion of the secreting cell's body is lost during secretion. The term Apocrine gland is often used to refer to the apocrine sweat glands, however it is thought that apocrine sweat glands may not be true apocrine glands as they may not use the apocrine method of secretion. (e.g. mammary gland, sweat gland of arm pit, pubic region, skin around anus, lips and nipples) Holocrine glands – the entire cell disintegrates to secrete its substances. (e.g. sebaceous glands: meibomian and zeis glands) Exocrine glands can further be categorized by their product:
A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops in one of the arteries of the heart, causing infarction (tissue death) to the heart muscle. The most common symptom is retrosternal chest pain or discomfort that classically radiates to the left shoulder, arm, or jaw. The pain may occasionally feel like heartburn. This is the dangerous type of acute coronary syndrome. Other symptoms may include shortness of breath, nausea, feeling faint, a cold sweat, feeling tired, and decreased level of consciousness. Women more often present without chest pain and instead have neck pain, arm pain or feel tired. Among those over 70-75 years old, about 5% have had an MI with little or no history of symptoms. An MI may cause heart failure, an irregular heartbeat, cardiogenic shock or cardiac arrest. Most MIs occur due to coronary artery disease. Risk factors include high blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol, poor diet, and excessive alcohol intake. The complete blockage of a coronary artery caused by a rupture of an atherosclerotic plaque is usually the underlying mechanism of an MI. MIs are less commonly caused by coronary artery spasms, which may be due to cocaine, significant emotional stress (often known as Takotsubo syndrome or broken heart syndrome) and extreme cold, among others. Many tests are helpful with diagnosis, including electrocardiograms (ECGs), blood tests and coronary angiography.
In early 1987, he persuaded 11 Doobie alumni to join him for a concert to benefit veterans' causes. Answering the call were Tom Johnston, Pat Simmons, Jeff Baxter, John McFee, John Hartman, Michael Hossack, Chet McCracken, Michael McDonald, Cornelius Bumpus, Bobby LaKind and Tiran Porter, plus their long-time record producer and good friend, Ted Templeman. There were no surplus bass players as Weeks had other commitments. They soon discovered that tickets were in great demand, so the concert quickly evolved into a 12-city tour that began on May 21, 1987, in San Diego. The third concert, held at the Hollywood Bowl, was reportedly the venue's fastest sell-out since the Beatles had played there just over 20 years earlier. The band performed selections from every album using a wide variety of instrumentation that they could not have previously duplicated onstage without the expanded lineup. Baxter and McFee played pedal steel and violin, respectively, during "Black Water" and "Steamer Lane Breakdown". "Without You" featured four drummers and four lead guitarists. Producer Ted Templeman played percussion and LaKind sometimes played Knudsen's drum set while Knudsen went to the front of the stage to join the chorus. Templeman also played the drum set on "What a Fool Believes", as he did on the original hit record. The tour culminated (sans McDonald, LaKind, McFee and Knudsen) at the Glasnost-inspired July 4 "Peace Concert" in Moscow, with Bonnie Raitt, James Taylor and Santana sharing the bill.
Sources: en.wikipedia.org
After Count Henry's death in 1112, Teresa ruled Portugal as queen. Her close association from 1121 with Fernando Pérez de Traba, a Galician noble, displeased the local nobility, who sided with her son, Afonso Henriques, defeating her and her supporters at the Battle of São Mamede in 1128. The following year, Afonso claimed sole authority over the entire county, free from foreign influence. According to legend, he won the Battle of Ourique and took the title of King in 1139. Afonso's claim was implicitly recognised by Alfonso VII of León at the Conference of Zamora in 1143, and by Pope Alexander III in 1179 through the papal bull Manifestis Probatum. With the support of north-European crusaders and Christian military and religious orders, Afonso Henriques and his successors continued pushing south until the capture of Algarve, the southernmost region of mainland Portugal, which was recognised by the Kingdom of Castile as Portuguese territory in 1267. With minor readjustments, Portugal's borders have largely remained the same since the signing of the Treaty of Alcañices between Denis of Portugal and Fernando IV of Castile in 1297. Between the 14th and early 15th century, Portugal was struck by several outbreaks of the plague, civil wars, invasions, famines, and natural disasters that led to a population decrease, labour shortages, and rise in antisemitism.
== Prognosis == The prognosis for alpha thalassemia depends on the degree to which alpha globin production is affected. Those with mild alpha thalassemia, involving deletion of one or two alpha-globin genes, do not generally require treatment and have a normal life expectancy. Hemoglobin H disease, with three of the four genes either deleted or inactive, gives a mild to moderate form of anemia but may lead normal lives. The prognosis when all four genes are affected, leading to Hb Bart's hydrops fetalis, is very poor, with most affected fetuses dying in utero or shortly after birth due to severe fetal hypoxia. It can be treated with intrauterine transfusions, however survival remains low and the infant requires lifelong blood transfusions. As of 2017, 69 patients were known who have survived past infancy.
euploidy The condition of a cell or organism having an abnormal number of complete sets of chromosomes, possibly excluding the sex chromosomes. Euploidy differs from aneuploidy, in which a cell or organism has an abnormal number of one or more specific individual chromosomes.
Sources: en.wikipedia.org
==== Inclusion of plasticizers ==== Inclusion of plasticizers tends to lower Tg and increase polymer flexibility. Addition of the plasticizer will also modify dependence of the glass-transition temperature Tg on the cooling rate. The mobility of the chain can further change if the molecules of plasticizer give rise to hydrogen bonding formation. Plasticizers are generally small molecules that are chemically similar to the polymer and create gaps between polymer chains for greater mobility and fewer interchain interactions. A good example of the action of plasticizers is related to polyvinylchlorides or PVCs. A uPVC, or unplasticized polyvinylchloride, is used for things such as pipes. A pipe has no plasticizers in it, because it needs to remain strong and heat-resistant. Plasticized PVC is used in clothing for a flexible quality. Plasticizers are also put in some types of cling film to make the polymer more flexible.
=== Occurrence === Glutathione is the most abundant non-protein thiol (R−SH-containing compound) in animal cells, ranging from 0.5 to 10 mmol/L. It is present in the cytosol and organelles. The concentration of glutathione in the cytoplasm is significantly higher (ranging from 0.5-10 mM) compared to extracellular fluids (2-20 μM), reaching levels up to 1000 times greater. In healthy cells and tissue, more than 90% of the total glutathione pool is in the reduced form (GSH), with the remainder in the disulfide form (GSSG). The cytosol holds 80-85% of cellular GSH, and the mitochondria hold 10-15%. Human beings synthesize glutathione, but a few eukaryotes do not, including some members of Fabaceae, Entamoeba, and Giardia. The only known archaea that make glutathione are halobacteria. Some bacteria, such as "Cyanobacteria" and Pseudomonadota, can biosynthesize glutathione. The systemic availability of orally administered glutathione is poor. It has low bioavailability because the tripeptide is the substrate of proteases (peptidases) of the alimentary canal, and due to the absence of a specific carrier of glutathione at the level of the cell membrane. The administration of N-acetylcysteine (NAC), a cysteine prodrug, helps replenish intracellular GSH levels.
Currently, three proteins from the pathway have been identified, of which include D-lactate dehydrogenase, phosphotransacetylase, and the acetate kinase. The acetate kinase specifically acts to catabolize D-lactate for substrate-level phosphorylation of ADP into ATP, producing acetate as a byproduct. This pathway, which takes place in the cytoplasm, can also generate ATP by assisting the maintenance of the electrochemical gradient that lies between the periplasm and cytoplasm of T.pallidum.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.